Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Nanjing Leads Biolabs Co., Ltd. Class H ( (HK:9887) ) has provided an update.
Nanjing Leads Biolabs Co., Ltd. issued a clarification announcement regarding its recent Exclusive Global License Agreement. The revised announcement includes additional details about potential near-term milestone payments, enhancing transparency for investors and superseding the previous announcement.
The most recent analyst rating on (HK:9887) stock is a Buy with a HK$80.27 price target. To see the full list of analyst forecasts on Nanjing Leads Biolabs Co., Ltd. Class H stock, see the HK:9887 Stock Forecast page.
More about Nanjing Leads Biolabs Co., Ltd. Class H
Nanjing Leads Biolabs Co., Ltd. is a joint stock company based in the People’s Republic of China, operating in the biopharmaceutical industry. The company focuses on developing and commercializing innovative therapies and has a market presence through its listing on the Hong Kong Stock Exchange.
Average Trading Volume: 1,702,260
For detailed information about 9887 stock, go to TipRanks’ Stock Analysis page.